These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24218264)

  • 1. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).
    Roumenina LT; Roquigny R; Blanc C; Poulain N; Ngo S; Dragon-Durey MA; Frémeaux-Bacchi V
    Methods Mol Biol; 2014; 1100():237-47. PubMed ID: 24218264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
    Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
    Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator.
    Nozal P; Garrido S; Alba-Domínguez M; Espinosa L; Peña A; Córdoba SR; Sánchez-Corral P; López-Trascasa M
    Mol Immunol; 2014 Apr; 58(2):194-200. PubMed ID: 24378252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.
    Kopp A; Strobel S; Tortajada A; Rodríguez de Córdoba S; Sánchez-Corral P; Prohászka Z; López-Trascasa M; Józsi M
    J Immunol; 2012 Aug; 189(4):1858-67. PubMed ID: 22786770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
    Hirt-Minkowski P; Dickenmann M; Schifferli JA
    Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes.
    Le Quintrec M; Roumenina L; Noris M; Frémeaux-Bacchi V
    Semin Thromb Hemost; 2010 Sep; 36(6):641-52. PubMed ID: 20865641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical hemolytic uremic syndrome.
    Kavanagh D; Goodship TH
    Curr Opin Hematol; 2010 Sep; 17(5):432-8. PubMed ID: 20613506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
    Dragon-Durey MA; Blanc C; Marliot F; Loirat C; Blouin J; Sautes-Fridman C; Fridman WH; Frémeaux-Bacchi V
    J Med Genet; 2009 Jul; 46(7):447-50. PubMed ID: 19435718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
    Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
    Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.
    Blanc C; Roumenina LT; Ashraf Y; Hyvärinen S; Sethi SK; Ranchin B; Niaudet P; Loirat C; Gulati A; Bagga A; Fridman WH; Sautès-Fridman C; Jokiranta TS; Frémeaux-Bacchi V; Dragon-Durey MA
    J Immunol; 2012 Oct; 189(7):3528-37. PubMed ID: 22922817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
    Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.
    Frimat M; Tabarin F; Dimitrov JD; Poitou C; Halbwachs-Mecarelli L; Fremeaux-Bacchi V; Roumenina LT
    Blood; 2013 Jul; 122(2):282-92. PubMed ID: 23692858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
    Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
    J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome.
    Boels MG; Lee DH; van den Berg BM; Dane MJ; van der Vlag J; Rabelink TJ
    Eur J Intern Med; 2013 Sep; 24(6):503-9. PubMed ID: 23357408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome.
    Francis NJ; McNicholas B; Awan A; Waldron M; Reddan D; Sadlier D; Kavanagh D; Strain L; Marchbank KJ; Harris CL; Goodship TH
    Blood; 2012 Jan; 119(2):591-601. PubMed ID: 22058112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
    Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
    Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical hemolytic uremic syndrome due to factor H autoantibody.
    Uslu-Gökceoğlu A; Doğan CS; Comak E; Koyun M; Akman S
    Turk J Pediatr; 2013; 55(1):86-9. PubMed ID: 23692839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome.
    Heinen S; Sanchez-Corral P; Jackson MS; Strain L; Goodship JA; Kemp EJ; Skerka C; Jokiranta TS; Meyers K; Wagner E; Robitaille P; Esparza-Gordillo J; Rodriguez de Cordoba S; Zipfel PF; Goodship TH
    Hum Mutat; 2006 Mar; 27(3):292-3. PubMed ID: 16470555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.